Impact of stress hyperglycemia ratio, derived from glycated albumin or hemoglobin A1c, on mortality among ST-segment elevation myocardial infarction patients
Authors' conclusion
SHR1 and SHR2 have emerged as robust and independent prognostic markers for STEMI patients undergoing PCI. The SHR calculation based on either HbA1c or GA can provide additional predictive value for mortality beyond traditional risk factors, helping to identify high-risk STEMI patients.
Study context
- Population
- STEMI patients who underwent percutaneous coronary intervention (PCI) in two centres
- Participants
- 1,643 patients
- Exposure
- Stress hyperglycemia ratio (SHR) derived from glycated albumin (GA) vs from hemoglobin A1c (HbA1c) as prognostic markers
- Outcome
- In-hospital death and all-cause mortality
- Follow-up
- Median 1.56 years
Methodological detailstwo centres
- Two centres
Main finding
As reported in the abstract
Per SD increase in SHR1: increase in in-hospital death
39%
Per SD increase in SHR1: increase in all-cause mortality
22%
Per SD increase in SHR2: increase in in-hospital death
51%
Per SD increase in SHR2: increase in all-cause mortality
26%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| AUC for in-hospital death, SHR1 vs SHR2Not significantly different | P > 0.05 |
Adding SHR1 or SHR2 to base model
- Significantly improved discrimination and risk reclassification for in-hospital and all-cause mortality
Subgroup: hypercholesteremia
- Effects of SHR1 and SHR2 more pronounced in patients with hypercholesteremia
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →